ADMA Biologics posts preliminary 2025 revenue update

ADMA Biologics, Inc. filed a current report describing that it has issued a press release with preliminary, unaudited full year 2025 revenue figures and a broader business update.

Accepted by SEC EDGAR 01/12/2026 - 08:20 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ADMA Biologics, Inc. filed a current report describing that it has issued a press release with preliminary, unaudited full year 2025 revenue figures and a broader business update. The company notes that these results are subject to completion of its accounting and annual audit procedures and may change once the audit is finished, so they should be viewed as early estimates rather than final numbers.

ADMA is also making available a Corporate Presentation it expects to use in meetings with potential investors, strategic partners, industry analysts and others. Both the press release and the presentation are provided as exhibits to the report and are described as being furnished, not filed, which means they are not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ADMA (ADMA) disclose in its latest 8-K filing?

ADMA Biologics disclosed that it released a press release with preliminary unaudited full year 2025 revenue and a business update, and furnished an investor Corporate Presentation.

Are ADMA Biologics’ full year 2025 revenue figures final in this 8-K?

No. The 8-K explains that the full year 2025 revenue figures are preliminary and unaudited and are subject to change after completion of ADMA Biologics’ accounting and annual audit procedures.

What investor materials did ADMA Biologics include with this 8-K?

ADMA Biologics attached a press release as Exhibit 99.1 and a January 2026 Corporate Presentation as Exhibit 99.2, which it expects to use in presentations to potential investors and other stakeholders.

How are the press release and presentation treated under securities laws?

The company states that the information in Items 2.02 and 7.01, including the press release and Corporate Presentation, is being furnished and not filed, and therefore is not automatically subject to certain Exchange Act liabilities or incorporation by reference unless specifically included in another filing.

Where can investors find ADMA Biologics’ Corporate Presentation mentioned in the 8-K?

The 8-K states that the Corporate Presentation is attached as Exhibit 99.2 and is also available on ADMA Biologics’ website under the “Company Information” tab in the “Investors” section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000136851400013685142026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

ADMA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36728	56-2590442
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey		07446
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ADMA	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, ADMA Biologics, Inc. (the “Company”) issued a press release announcing the Company’s preliminary unaudited full year 2025 revenue and providing a business update. The results included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company’s accounting and annual audit procedures and are, therefore, subject to adjustment. Additional information and disclosures are required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*

Item 7.01 Regulation FD.

The Company hereby furnishes the Corporate Presentation the Company expects to present, in whole or in part, and possibly with modifications, from time to time in connection with presentations to potential investors, strategic partners, industry analysts and others. The Corporate Presentation is attached hereto as Exhibit 99.2 and is incorporated by reference herein, and is available under the “Company Information” tab in the “Investors” section of the Company’s website, located at www. admabiologics.com.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.*

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of the Company, dated as of January 12, 2026.
99.2	ADMA Biologics, Inc. January 2026 Corporate Presentation.
104	Cover Page Interactive Data File (embedded with the Inline XBRL document)

* The information in Item 2.02 and Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 12, 2026	ADMA Biologics, Inc.
	By:	/s/ Adam S. Grossman
		Name:	Adam S. Grossman
		Title:	President and Chief Executive Officer